Kite Pharma, Roche to co-develop two new treatments for non-hodgkin lymphoma

pharmafile | March 18, 2016 | News story | Medical Communications, Research and Development Gentech, Roche, kite pharma, non-Hodgkin lymphoma 

Kite Pharma (Nasdaq: KITE) said it will collaborate with Swiss drug major Roche (SIX: ROG) to evaluate the safety and efficacy of its drug compound in combination with KTE-C19, in combination with atezolizumab to treat non-Hodgkin lymphoma (NHL).

The company said it expects to start multi-center Phase I/ II study with Genentech, a unit of Roche, in 2016. 

Arie Belldegrun, chief executive of Kite, says: “Kite is a pioneer in engineered T cell therapy, and we are excited to collaborate with Genentech, an industry leader with a history of developing transformative therapies for cancer. KTE-C19 is currently in four pivotal studies and early clinical findings have shown a potential for breakthrough efficacy in refractory, aggressive NHL and other B cell malignancies.  The scientific rationale for combining KTE-C19 and atezolizumab in refractory, aggressive NHL is compelling, and could potentially lead to opportunities to advance this combination in other indications.”

Advertisement

KTE-C19 is an investigational immunotherapy in which a patient’s T cells are genetically modified to express a CAR designed to target the antigen CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias.  Atezolizumab is an investigational monoclonal antibody designed to target and bind to a protein called PD-L1, which is expressed on tumor cells and tumor-infiltrating immune cells.  

Anjali Shukla

Related Content

Roche secures CE Mark for automated latent tuberculosis blood test

Roche has received CE Mark approval for its Elecsys IGRA TB test, an automated blood …

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

Roche has expanded its global AI infrastructure with a NVIDIA AI factory, adding 2,176 high-performance …

Roche receives CE Mark for blood test to help rule out Alzheimer’s

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

The Gateway to Local Adoption Series

Latest content